b|**e**|**i** resources

SUPPORTING INFECTIOUS DISEASE RESEARCH

Klebsiella pneumoniae, Strain MRSN 13768

Catalog No. NR-55517

This reagent is the tangible property of the U.S. Government.

Product Description:

Klebsiella pneumoniae (K. pneumoniae), strain MRSN 13768 was isolated in 2011 from a human blood sample in Europe as part of a global surveillance program. NR-55517 was deposited as an extensively drug-resistant strain, sensitive to amikacin, ceftazidime/avibactam, gentamicin, tigecycline and trimethoprim/sulfamethoxazole and resistant to ampicillin/sulbactam, aztreonam, cefepime, ceftazidime, ceftolozane/tazobactam, ceftriaxone, ciprofloxacin, ertapenem, imipenem, levofloxacin, meropenem, piperacillin/tazobactam, tetracycline and tobramycin. NR-55517 was produced by inoculation of the deposited material into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar kolles, which were grown for 1 day at 37°C in an aerobic atmosphere to produce this lot. Quality control testing was completed under propagation conditions unless otherwise noted.

Lot: 70049649

Manufacturing Date: 06JAN2022

BEI Resources is committed to ensuring digital accessibility for people with disabilities. This Certificate of Analysis contains complex tables and may not be fully accessible. Please let us know if you encounter accessibility barriers and a fully accessible document will be provided: E-mail: <u>Contact@BEIResources.org</u>. We try to respond to feedback within 24 hours.

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis		
Cellular morphology	Gram-negative rods	Gram-negative rods
Colony morphology	Report results	Circular, convex, entire, mucoid and cream (Figure 1)
Motility (wet mount)	Report results	Non-motile
VITEK [®] MS (MALDI-TOF)	K. pneumoniae	K. pneumoniae (99.9%)
Antibiotic Susceptibility Profile ^{1,2}		
Amikacin	Sensitive	Sensitive (8 to 16 µg/mL)
Ampicillin/sulbactam	Resistant	Resistant (≥ 32 µg/mL)
Aztreonam	Resistant	Resistant (≥ 64 µg/mL)
Cefepime	Resistant	Resistant (≥ 64 µg/mL)
Ceftazidime	Resistant	Resistant (≥ 64 µg/mL)
Ceftazidime/avibactam	Sensitive	Sensitive (4 µg/mL)
Ceftolozane/tazobactam	Resistant	Resistant (> 256 µg/mL)
Ceftriaxone	Resistant	Resistant (≥ 64 µg/mL)
Ciprofloxacin	Resistant	Resistant (> 32 µg/mL)
Ertapenem	Resistant	Resistant (≥ 8 µg/mL)
Gentamicin	Sensitive	Sensitive (≤ 1 μg/mL)
Imipenem	Resistant	Resistant (> 32 µg/mL)
Levofloxacin	Resistant	Resistant (≥ 8 µg/mL)
Meropenem	Resistant	Resistant (≥ 16 µg/mL)
Piperacillin/tazobactam	Resistant	Resistant (≥ 128 µg/mL)
Tetracycline	Resistant	Resistant (≥ 16 µg/mL)
Tigecycline	Sensitive	Inconclusive ^{3,4}
Tobramycin	Resistant	Resistant (≥ 16 µg/mL)
Trimethoprim/sulfamethoxazole	Sensitive	Sensitive (≤ 20 µg/mL)
Genotypic Analysis		
Sequencing of 16S ribosomal RNA gene (~ 1470 base pairs)	≥ 99% sequence identity to <i>K. pneumoniae</i> , strain MRSN 13768 (GenBank: JAGYEP010000113.1)	99.5% sequence identity to <i>K. pneumoniae</i> , strain MRSN 13768 (GenBank: JAGYEP010000113.1) ⁵

E-mail: <u>contact@beiresources.org</u> Tel: 800-359-7370 Fax: 703-365-2898

Certificate of Analysis for NR-55517

SUPPORTING INFECTIOUS DISEASE RESEARCH

TEST	SPECIFICATIONS	RESULTS
Purity 7 days at 37°C in an aerobic atmosphere with and without 5% CO ₂ on Tryptic Soy agar	Growth consistent with expected colony morphology	Growth consistent with expected colony morphology
Viability	Growth	Growth

¹Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)

²Antibiotic susceptibility was tested using a combination of bioMérieux VITEK[®]2 GN74 and ETEST[®].

³K. pneumoniae, strain MRSN 13768 was deposited as being sensitive to tigecycline. Antibiotic susceptibility testing performed in duplicate determined that for strain MRSN 13768, the tigecycline MICs are 1 µg per mL and 2 µg per mL, which are interpreted as sensitive and resistant, respectively. ⁴MIC Interpretation Guideline: EUCAST Version 8.0 (2018)

⁵Also consistent with other *Klebsiella* species

Figure 1: Colony Morphology

/Sonia Bjorum Brower/ Sonia Bjorum Brower

Lead Technical Writer or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC[®] is a trademark of the American Type Culture Collection. You are authorized to use this product for research use only. It is not intended for human use.



11 AUG 2022

